Abstracts Archive - Page 351 of 2616 - ACR Meeting Abstracts

Abstract Number: 0509 • ACR Convergence 2024
Trends in Initiation of Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis Among Commercially-Insured US Adults, 2001-2021
Lydia Lee¹, Jeffrey Sparks², Priyanka Yalamanchili¹, Daniel B. Horton³, Zeba Khan⁴, Joseph Barone⁴ and Chintan Dave⁵, ¹Rutgers University, New Brunswick, NJ, ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA, ³Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy, and Aging Research; Department of Biostatistics and Epidemiology, Rutgers School of Public Health; Department of Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ⁴Rutgers University, New Brunswick, ⁵Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy, and Aging Research; Center for Health Outcomes, Policy & Economics, Rutgers Ernest Mario School of Pharmacy and Rutgers School of Public Health, New Brunswick, NJ
Background/Purpose: Despite the increasing availability of newer RA therapies, there is a paucity of data comprehensively evaluating long-term trends for individual DMARDs in the US.…
Abstract Number: 0484 • ACR Convergence 2024
Cluster Analysis Based on Joint Characteristics: A Study of Joint Involvement Profiles in Early Rheumatoid Arthritis (ERA) Patients in China
Yafang Deng¹, Chen Yu², Lin Qiao¹, Nan Jiang¹, Yanhong Wang³, Xinping Tian¹, Qian Wang¹, Mengtao Li⁴ and Xiaofeng Zeng¹, ¹Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ²Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Dong Cheng Qu, China (People's Republic), ³Department of Epidemiology and Biostatistics, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ⁴Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China 2National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, Beijing, China
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic inflammatory autoimmune disorder characterized by aggressive articular damage, and articular symptoms are often the initial and significant clinical…
Abstract Number: 0505 • ACR Convergence 2024
UseofaMolecularSignatureResponseClassifiertoPredictInadequateResponsetoTNFiResultsinFewer Patients Prescribed TNFi
George Karpouzas¹, Lixia Zhang², Mark Zielinski², Brian Cheng² and Sherry Guardiano³, ¹Harbor-UCLA Medical Center, Torrance, CA, ²Scipher Medicine Corporation, Waltham, MA, ³Scipher Medicine Corporation, Keene, NH
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are generally the first class of biologic disease modifying anti-rheumatic drugs (DMARDs) prescribed for rheumatoid arthritis (RA) patients with…
Abstract Number: 0534 • ACR Convergence 2024
Patient Reported Outcomes and Disease Activity from a Phase 1 Double-Blind Randomized Clinical Trial of Allogeneic Mesenchymal Stem Cells in Early Rheumatoid Arthritis
Alexandre Matar¹, Maya Breitman², Tracey Bonfield³, Maricela Haghiac⁴, Jane Reese³, Emma Barnboym⁵, Steven Lewis⁶, Hillard Lazarus⁷ and Nora Singer⁸, ¹MetroHealth, Westlake, OH, ²MetroHealth Medical Center,Case Western Reserve University School of Medicine, Cleveland, OH, ³Case Western Reserve University, Cleveland, OH, ⁴Metrohealth Medical Center, Cleveland, OH, ⁵The MetroHealth System, Cleveland, OH, ⁶Case Western University, MetroHealth, Cleveland, OH, ⁷Case Western Reserve University/University Hospitals, Cleveland, OH, ⁸MetroHealth System at Case Western Reserve University School of Medicine, Cleveland, OH
Background/Purpose: Mesenchymal stem (stromal) cells (MSCs) constitute an emerging therapeutic strategy for several human diseases. Small non-randomized studies have shown that MSCs may be a…
Abstract Number: 0525 • ACR Convergence 2024
Assess the Effect of Increasing the Dose of Folic Acid Supplementation in Patients of Rheumatoid Arthritis with Methotrexate Intolerance – A Randomised Controlled Trial
Varun Dhir¹, Harshith Sai Koneti², Aman Sharma³, sanjay jain⁴ and shankar naidu⁵, ¹PGIMER, CHD, INDIA, CHANDIGARH, India, ²PGIMER, Chandigarh, Sangareddy, Telangana, India, ³PGIMER, Chandigarh, India, Chandigarh, Chandigarh, India, ⁴PGIMER, Chandigarh, Chandigarh, India, ⁵PGIMER, Chandigarh, India, Chandigarh, India
Background/Purpose: : Methotrexate (MTX) Intolerance continues to occur in 20-40% patients despite low-dose folic acid (5-10mg per week) supplementation. Would a higher dose of folic…
Abstract Number: 0518 • ACR Convergence 2024
Sustained Patient Meaningful Outcomes of Pain and Fatigue Relief and Improved Physical Functioning with Filgotinib in Rheumatoid Arthritis: A Post Hoc Analysis
Rieke Alten¹, Bruno Fautrel², Philip G Conaghan³, Dick de Vries⁴, Margaux Faes⁵, Mercedes Piovesan⁶, Katrien Van Beneden⁷, Chris Watson⁸, Angelique E.A.M. Weel-Koenders⁹, Eugen Feist¹⁰ and Kurt de Vlam¹¹, ¹Department of Internal Medicine and Rheumatology, Schlosspark Klinik, University Medicine Berlin, Berlin, Germany, ²INSERM, UMRS 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Sorbonne University – Assistance Publique-Hôpitaux de Paris, Département de Rhumatologie, Hôpital Pitié-Salpêtrière, Paris, Ile-de-France, France, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁴Clinical Development, Galapagos BV, Leiden, Netherlands, ⁵Biostatistics, Galapagos NV, Mechelen, Belgium, ⁶Medical Affairs, Galapagos Biopharma Spain SLU, Madrid, Spain, ⁷Medical Affairs, Galapagos NV, Mechelen, Belgium, ⁸Medical Affairs, Galapagos Biotech Ltd, Cambridge, United Kingdom, ⁹Erasmus School of Health Policy and Management, Erasmus University Rotterdam, and Department of Rheumatology and Clinical Immunology, Maasstad Hospital, Rotterdam, Netherlands, ¹⁰Department of Rheumatology, Helios Clinic Vogelsang-Gommern, cooperation partner of the Otto von Guericke University Magdeburg, Gommern, Germany, ¹¹Department of Rheumatology, UZ Leuven, and Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, KU Leuven, Leuven, Belgium
Background/Purpose: Quality of life for patients with RA can be severely impacted by pain, fatigue and impaired physical functioning.1 Filgotinib (FIL) has demonstrated early onset…
Abstract Number: 0529 • ACR Convergence 2024
Discontinuation of Targeted Disease-Modifying Antirheumatic Agents in Older Patients with Rheumatoid Arthritis: Retrospective Analysis of Medicare Data
Yinan Huang¹, Shadi Bazzazzadehgan², Sebastian Bruera³ and Sandeep Agarwal³, ¹University of Mississippi School of Pharmacy, Oxford, MS, ²University of Mississippi School of Pharmacy, Oxford, ³Baylor College of Medicine, Houston
Background/Purpose: Individuals with rheumatoid arthritis (RA) may discontinue b/tsDMARDs due to treatment failure, adverse events or costs. Little is known about b/tsDMARDs discontinuation among Medicare…
Abstract Number: 0528 • ACR Convergence 2024
Consequences of Switching Originator Biological Therapies to Its Biosimilars in Patients with Immune-mediated Diseases in a Mexican Cohort
Sandra Carrillo¹, Daniel Xibille², Martha Mariana Castañeda-Martínez³, Alfredo Reyes⁴, Brian garcia-Arellano⁵, Edgar Vega Chávez⁶, Carlos vidal Montiel Castañeda⁵, Gabriel Carmona Lara⁶ and Gilberto De Hoyos⁵, ¹Hospital Angeles Lindavista, Mexico City, Distrito Federal, Mexico, ²Servicios de Salud de Morelos, Cuernavaca, Morelos, Mexico, ³ISSSTE, Monterrey, Mexico, ⁴ISSSTE, Ciudad de México, Mexico, ⁵ISSSTE, Ciudad de México, Distrito Federal, Mexico, ⁶ISSSTE, Ciudad de mexico, Distrito Federal, Mexico
Background/Purpose: Biological agents such as the TNF-α inhibitors have had a positive impact on the treatment of many chronic autoimmune diseases (AIDs), such as Rheumatoid…
Abstract Number: 0521 • ACR Convergence 2024
Transcriptome Analysis of Drug Response in a Large Cohort of Immune-Mediated Inflammatory Disease Patients Supports Advanced Combination Therapy in Rheumatoid Arthritis
Ernest Choy¹, Maria López Lasanta², Paloma Vela-Casasempere³, Antonio Fernandez Nebro⁴, Santos Castañeda⁵, Carlos Marras⁶, Jaime Calvo-Alén⁷, Jesus Tornero⁸, Juan Cañete⁹, Eugeni Domènech¹⁰, Javier Gisbert¹¹, José Manuel Carrascosa¹², Eduardo Fonseca¹³, Luis Bujanda¹⁴, Valle García¹⁵, Britta Siegmund¹⁶, Giampiero Girolomoni¹⁷, Holger Heyn¹⁸, Pere Santamaria¹⁹, Richard M Myers²⁰, yolanda Guillen²¹, Sergio H Martínez-Mateu²², Sara Marsal²³ and Antonio Julia²⁴, and IMID Consortium, ¹Cardiff University School of Medicine, Cardiff, United Kingdom, ²Hospital Universitari Vall d´Hebron, Rheumatology, Barcelona, Spain, ³Hospital General Universitario Alicante, Alicante, Spain, ⁴Hospital Regional Universitario Carlos Haya , Rheumatology, Málaga, Spain, ⁵Hospital Universitario de la Princesa, Madrid, Spain, ⁶Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Murcia, Spain, ⁷Department of Rheumatology, Hospital Araba, Vitoria, Pais Vasco, Spain, ⁸Hospital Universitario de Guadalajara, Guadalajara, Spain, ⁹Hospital Clinic an IDIBAPS, Barcelona, Spain, ¹⁰Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ¹¹Hospital Universitario de la Princesa and IIS-IP, Madrid, Spain, ¹²Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ¹³Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain, ¹⁴Hospital Universitario de Donostia, San Sebastián, Spain, ¹⁵Hospital Universitario Reina Sofía, Córdoba, Spain, ¹⁶Charité – Universitätsmedizin Berlin, Berlin, Germany, ¹⁷University of Verona, Verona, Italy, ¹⁸Centre for Genomic Regulation (CNAG-CRG), National Centre for Genomic Analysis, Barcelona, Spain, ¹⁹Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, ²⁰HudsonAlpha Institute for Biotechnology, Huntsville, AL, ²¹Imidomics, Inc, Barcelona, Spain, ²²IMIDOMICs, Barcelona, Spain, ²³Vall Hebron Hospital Research Institute, Barcelona, Spain, ²⁴Vall d'Hebron Hospital Research Institute, Barcelona, Spain
Background/Purpose: Targeted therapies have failed to provide sustained disease remission in most patients suffering from immune-mediated inflammatory diseases (IMIDs). Combining existing drugs could overcome this…
Abstract Number: 0513 • ACR Convergence 2024
Effects of Cumulative Rituximab Exposure in Patients with Rheumatoid Arthritis: Results from Cohort at a Tertiary Academic Health Care Setting
Ioasaf Karafotias¹, Maryam Adas¹, Katie Bechman¹, Nicholas Williamson¹, Mark Hughes¹, Daksh Mehta², Ritika Roy¹, Sam Norton³ and James Galloway⁴, ¹King's College London, London, United Kingdom, ²King's College Hospital, London, United Kingdom, ³King's College London, London, England, United Kingdom, ⁴Centre for Rheumatic Diseases, King's College London, London, United Kingdom
Background/Purpose: Rituximab targets CD20-positive B cells and is used to treat rheumatoid arthritis (RA). B cell depletion may result in hypogammaglobulinemia. Hypogammaglobulinemia is a risk…
Abstract Number: 0488 • ACR Convergence 2024
Association of Anti-CarP Levels with Clinical Activity and Serological Profile in Rheumatoid Arthritis
Pablo Martínez Calabuig¹, Elena Grau García², Samuel Leal Rodriguez², Ernesto Tovar Sugrañes³, José Ivorra-Cortés⁴, Carmen Riesco Barcena³, Anderson Huaylla Quispe³, Laura Mas Sánchez⁵, Pablo Muñoz Martínez⁶, Daniel Ramos Castro³, Alba Torrat noves⁷, Iago Alcantara Alvarez⁸, Belén Villanueva Mañés⁸, Miguel Simeo Vinaixa⁸, Andrés Pérez Hurtado³ and Jose A Román-Ivorra⁹, ¹HOSPITAL GENERAL UNIVERSITARIO VALENCIA SPAIN, Ontinyent, Comunidad Valenciana, Spain, ²HUP La Fe, Valencia, Spain, ³Rheumatology Department. HUP La Fe, Valencia, Spain, ⁴Hospital Universitario La Fe, PALMA DE MALLORCA, Spain, ⁵Resident at Hospital Universitari i Politecnic La Fe, Valéncia, Spain, ⁶Hospital Universitario y Politècnico La Fe, Sagunto, Spain, ⁷Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Comunidad Valenciana, Spain, ⁸Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, ⁹Hospital Universitari i Politècnic la Fe, Valencia, Comunidad Valenciana, Spain
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease where the presence of rheumatoid factor (RF) and anti-citrullinated peptide antibodies (antiCCP) has been associated to…
Abstract Number: 0486 • ACR Convergence 2024
Associations Between Frailty and Incident Cancer and Cancer-related Mortality in Veterans with Rheumatoid Arthritis
Bhavik Bansal¹, Aaron Baraff², Katherine Wysham³, James Andrews⁴, Bryant England⁵, Ted Mikuls⁵, Joshua Baker⁶, Kaleb Michaud⁵, Alexa Meara⁷, Una Makris⁸, Carolyn Presley⁹, ariela orkaby¹⁰ and Namrata Singh¹¹, ¹All India Institute of Medical Sciences, New Delhi, Delhi, India, ²VA PUGET SOUND SEATTLE, Seattle, WA, ³VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵University of Nebraska Medical Center, Omaha, NE, ⁶University of Pennsylvania, Philadelphia, PA, ⁷The Ohio State University Wexner Medical Center, COLUMBUS, OH, ⁸UT Southwestern Medical Center and Dallas VA, Dallas, TX, ⁹The Ohio State Medical Center, Columbus, OH, ¹⁰New England VA Geriatric Research Education and Clinical Center/Boston VA/Division of Aging, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ¹¹University of Washington, Bellevue, WA
Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased risk of cancer compared to the general population. Aging is one of the most important risk…
Abstract Number: 0546 • ACR Convergence 2024
Hiding in Plain Sight: The Impact of Implementing an Automated Inflammatory Back Pain Screening Tool on the Identification of Axial Spondyloarthritis in a Community Rheumatology Practice
Nehad Soloman¹, Jawad Bilal² and John Tesser³, ¹Arizona Arthritis & Rheumatology Associates, P.C., Glendale, AZ, ²Arizona Arthritis & Rheumatology Associates, PC, Tucson, AZ, ³Arizona Arthritis and Rheumatology Associates, P.C., Phoenix, AZ
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic inflammatory disease affecting 1.4% of the US adult population. The leading clinical symptom of axSpA is chronic inflammatory…
Abstract Number: 0520 • ACR Convergence 2024
Disease Duration Differentially Affects the Clinical Efficacy of Biologics and JAK Inhibitors in Rheumatoid Arthritis: The ANSWER Cohort Study
Yoichi Nakayama¹, Daijiro Kabata², Wataru Yamamoto³, Hidehiko Makino⁴, Koji Nagai⁴, Naofumi Yoshida⁵, Yonsu Son⁵, Masaki Katayama⁶, Hirotaka Yamada⁷, Keisuke Nishimura⁷, Ryota Hara⁸, Ryu Watanabe⁹, Yuki Etani¹⁰, Kosuke Ebina¹¹, Hideo Onizawa¹², Takayuki Fujii¹³, Akira Onishi¹⁴, Kosaku Murakami¹⁵, Koichi Murata¹², Masao Tanaka¹⁴, Shuichi Matsuda¹², Akio Morinobu¹⁶, Ayumi Shintani² and Motomu Hashimoto⁹, ¹Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Hirakata-shi, Osaka-fu, Japan, ²Department of Medical Statistics, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan, ³Department of Health Information Management, Kurashiki Sweet Hospital, Kurashiki, Okayama, Japan, ⁴Department of Internal Medicine (IV), Osaka Medical and Pharmaceutical University, Osaka, Japan, ⁵First Department of Internal Medicine, Kansai Medical University, Hirakata, Osaka, Japan, ⁶Department of Rheumatology, Osaka Red Cross Hospital, Osaka, Japan, ⁷Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan, ⁸Department of Orthopaedic Surgery, Nara Medical University, Nara, Nara, Japan, ⁹Department of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan, ¹⁰Department of Sports Medical Biomechanics, Osaka University Graduate School of Medicine, Suita, Osaka, Japan, ¹¹Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Suita, Osaka, Japan, ¹²Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Graduate School of Medicine, Kyoto, Kyoto, Japan, ¹³Kyoto University, Kyoto, Japan, ¹⁴Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Graduate School of Medicine, Kyoto, Japan, ¹⁵Division of Clinical Immunology and Cancer Immunotherapy, Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan, ¹⁶Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan., Kyoto, Japan
Background/Purpose: A delay in initiating disease-modifying antirheumatic drugs (DMARDs) has been linked to poor outcomes in patients with rheumatoid arthritis (RA). Several studies have implicated…
Abstract Number: 0508 • ACR Convergence 2024
Real-World Evidence for GP2015 in Patients with Rheumatoid Arthritis: Safety Outcomes from German Observational Data
Xenofon Baraliakos¹, Cristofer Salvati², Elena Bachinskaya², Samriddhi Sinha² and Klaus Krüger³, ¹Rheumazentrum Ruhrgebiet Herne, and Ruhr-University Bochum, Bochum, Germany, ²Medical Affairs, Sandoz Hexal AG, Holzkirchen, Germany, Holzkirchen, Germany, ³Rheumatologisches Praxiszentrum, Munich, Germany, München, Germany
Background/Purpose: GP2015 is an etanercept biosimilar indicated for the treatment of rheumatoid arthritis (RA).1 The objective of this abstract is to describe the baseline characteristics…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].